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HINTERGRUND: Die Regeneration von Knorpel war seit jeher eine Herausforderung 
für das Tissue Engineering. Ständig erneuerte Erkenntnisse über die Rolle der 
Transformation der Proteinfamilie des Wachstumsfaktors Beta (TGF-β), die für 
verschiedene grundlegende biologische Prozesse bei der Gesundheit und Regeneration 
des Knorpels von entscheidender Bedeutung ist, haben neue Perspektiven für die 
Behandlung knorpelbedingter Erkrankungen eröffnet. In dieser Studie sollte untersucht 
werden, wie sich drei verschiedene Wachstumsfaktoren aus der TGF-β Supergenfamilie 
spezifisch auf das knochenmorphogenetische Protein 2 (BMP-2) auswirken. TGF-β3; 
osteogenes Protein 1 (OP-1), allein, jedoch insbesondere in verschiedenen 
Kombinationen, einschließlich unterschiedlicher Anwendungsdauer, sollte die 
Induktion der Chondrogenese im Muskelgewebe von Ratten bewirken. 
 
METHODEN: Es wurde Bauchmuskelgewebe von Ratten verwendet. Um zu 
überwachen, wie sich die Anwesenheit von Morphogen auf die Chondrogenese 
auswirkt, wurden in der „Entzugsstudie“ zwei Stimulationsarten untersucht. Hierbei 
handelte es sich um eine kontinuierliche Applikation relevanter Morphogene und ihrer 
Kombinationen über die gesamte Dauer der In-vitro-Kultur oder eine einmalige 
Applikation nur für 48 h. Die Nachweise wurden am Tag 7, 14 und 30 mittels 
Immunhistochemie (IHC), histologischer Färbung (Alcianblau-Färbung) und 
quantitativer Reverser Transkriptase-Polymerase-Kettenreaktion (qRT-PCR) 





Genexpressionsniveaus wurden analysiert, um das Überleben des Modells und der 
Chondrogenese zu bestätigen, einschließlich des vaskulären endothelialen 
Wachstumsfaktors A (VEGF-A), Kollagen Typ IV alpha 1 (Col4α1), 
geschlechtsbestimmende Region Y (SRY) -box 9 (SOX9), Aggrecan (ACAN), Kollagen 
Typ II alpha 1 (Col2α1), Kollagen Typ X alpha 1 (Col10α1), Kollagen Typ I alpha 1 
(Col1α1) und alkalische Phosphatase (ALP). 
 
ERGEBNISSE: Die Ergebnisse der qRT-PCR zeigten, dass die Hochregulierung der 
Genexpression für die kontinuierlichen Versuchsgruppen signifikant höher war als die 
der einzelnen 48h-Stimulationsgruppen. Die Gruppe mit BMP-2 allein zeigte am Tag 7 
kontinuierlich die höchsten relativen Expressionsniveaus, ausgedrückt als chondrogen-
verwandte Gene. Positive Reaktionen wurden bei der Alcianblau-Färbung und IHC mit 
semi-quantitativer histomorphometrischer Analyse beobachtet, die eine Korrelation zu 
der der Genexpressionsmuster zeigten. 
 
SCHLUSSFOLGERUNGEN: In dieser chondrogenen Induktionsstudie erwies sich 
Muskelgewebe als brauchbares Modell. Die Anwendung von Mitgliedern der TGF-β 
Supergenfamilie allein oder in Kombinationen induzierte die Chondrogenese in diesem 
Gewebemodell, wobei die Ergebnisse darauf schließen lassen, dass die Hyalinknorpel-
Chondrogenese auf der Grundlage der Col2α1 Expressionsmuster entwickelt wurde. 
Obwohl in diesem Projekt versucht wurde, mithilfe der Rückzugsstudie ein 





Stimulation mittels eines Wachstumsfaktors nicht ausreicht, um die entsprechende 
Reaktion hervorzurufen. Dies deutet stark darauf hin, dass eine kontinuierliche 
Stimulation erforderlich ist. Die Ergebnisse in dieser Hinsicht müssen jedoch mit 
Vorsicht interpretiert werden, da klar ist, dass ein einzelnes Morphogen eine begrenzte 
räumliche und zeitliche Wirkung hat, wenn das Vorhandensein des entsprechenden 
komplementären löslichen Signals (der entsprechenden komplementären löslichen 
Signale) zum richtigen Zeitpunkt vorliegen muss zur Gewährleistung einer 
ordnungsgemäßen und dauerhaften biologischen Reaktion bestimmter Pfade im Laufe 
der Zeit. Dies wurde durch BMP-2 veranschaulicht, dass allein die Chondrogenese 
initiieren konnte, jedoch bei Zugabe in Kombination mit TGF-β3 und / oder OP-1 
inhibiert wurde. Während BMP-2 anfänglich die Chondrogenese stimulierte, konnte es 
die relevante Reaktion im mittleren und späten Stadium der chondrogenen Induktion 
nicht aufrechterhalten, wobei TGF-β3 und OP-1 zur Aufrechterhaltung der Knorpel-
Tissue-Engineering-Reaktion erforderlich waren. Obwohl es noch Einschränkungen 
gibt, bieten die Experimente eine entscheidende Erkenntnis für das Tissue Engineering 
der TGF-β Supergenfamilie und liefern neue Erkenntnisse und Strategien für die 







BACKGROUND: The regeneration of cartilage has always been a challenge for tissue 
engineering. Constantly renewed insights into the role of transforming growth factor-
beta (TGF-β) supergene family of proteins, which are vital in several fundamental 
biological processes in cartilage health and regeneration, has opened up new prospects 
for the treatment of cartilage-related diseases. In this study, the aim was to investigate 
what the effect of three different growth factors from the TGF-β supergene family 
specifically [bone morphogenetic protein 2 (BMP-2); TGF-β3; osteogenic protein 1 
(OP-1)], alone but especially in varying combinations including application durations, 
would have on the induction of chondrogenesis in muscle tissue of rats. 
 
METHODS: Abdominal muscle tissue from rats was utilized. To monitor what the 
effect of morphogen presence would have on chondrogenesis, the “withdrawal study”, 
assessed two modes of stimulation. These were a continuous application of relevant 
morphogens and their combinations for the entire duration of the in vitro culture or a 
single application only for 48h. The detections were performed on day 7, 14 and 30 
using immunohistochemistry (IHC), histological staining (alcian blue staining) and 
quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). Aggrecan was 
treated as the target antigen in the IHC. The relative gene expression levels were 
analyzed to confirm the survival of the model and the chondrogenesis, including 
vascular endothelial growth factor A (VEGF-A), collagen type IV alpha 1 (Col4α1), 





alpha 1 (Col2α1), collagen type X alpha 1 (Col10α1), collagen type I alpha 1 (Col1α1) 
and alkaline phosphatase (ALP).  
 
RESULTS: The results of the qRT-PCR showed that the up-regulation in gene 
expression for the continuous experimental groups was more significant than that of the 
single 48h stimulation groups. The group with BMP-2 alone continuously presented the 
highest relative expression levels on day 7, in terms of the chondrogenic-related genes. 
Positive reactions were observed in the alcian blue staining and IHC with semi-
quantitative histomorphometrical analysis showing a correlation to that of the gene 
expression patterns.  
 
CONCLUSIONS: Muscle tissue was proven to be a viable model in this chondrogenic 
induction study. The application of members of the TGF-β supergene family, alone or 
in combinations, induced chondrogenesis in this tissue model, with results suggesting 
that hyaline cartilage chondrogenesis was being developed based on the Col2α1 
expression patterns. Although it was attempted to get a more economic-efficiency 
induction scheme using the withdraw-study in this project, it was shown that single 
stimulation of a growth factor was insufficient to evoke the relevant response, strongly 
suggesting that a continuous stimulation is necessary. However, the results in this regard 
have to be interpreted with care as it is clear that a single morphogen has a limited 
spatial and temporal effect where the presence of the appropriate corresponding 





proper and sustained biological reaction of specific pathways with time. This was 
exemplified by BMP-2 that on its own was able to initiate chondrogenesis, yet when 
added in combination with TGF-β3 and/or OP-1 was inhibited. However, while the 
BMP-2 initially stimulated chondrogenesis, it could not maintain the relevant reaction 
in the middle and late stages of chondrogenic induction, where TGF-β3 and OP-1 were 
necessary to maintain the cartilage tissue engineering reaction. Although limitations 
still exist, the experiments provide a crucial realization in the TGF-β supergene family 
tissue engineering prospect and deliver novel awareness and strategies in producing 







Regeneration of cartilage remains a challenge for tissue engineering. This introduction 
summarizes and reviews the current status of cartilage regeneration research in the light 
of relevant literature. At the same time, the role of the transforming growth factor-beta 
(TGF-β) supergene family of proteins in inducing chondrogenic morphogenesis are 
briefly described to illustrate the significance of this study. 
 
1.1 Cartilage and cartilage injure 
The skeletal system contains various types of tissue: bone, cartilage, muscle and fat, 
which are all derived from common mesenchymal progenitors1. Chondrogenesis is the 
initial process of skeletal development in embryogenesis of most long bones, which in 
which the formation of a cartilage anlage is first laid down that is eventually 
transformed into bone via the process of endochondral ossification. During this phase, 
mesenchymal cells are recruited and differentiate into chondroblasts; subsequently, the 
extracellular matrix (ECM) is formed by molecules, such as aggrecan and collagen type 
II, secreted by mature chondrocytes2,3. Hence, cartilage can be divided into three types 
according to its structure and function formed by different components. Hyaline 
cartilage is the predominant type in humans which forms all articular surfaces, with a 
specialized type of hyaline cartilage existing in the epiphyseal plate4,5. Fibrocartilage is 
a transitional type between connective tissue and cartilage, which is often distributed in 
the connection between intervertebral disc, glenoid, pubic symphysis and the 





last one is the elastic cartilage, which is present in the auricle and epiglottis8,9. For load-
bearing tissue, the relations between structure and function should be comprehended. 
Besides the extracellular water (66-78%), proteoglycans, collagen and additional 
specialized proteins, which constitute the cartilage matrix predominantly10, collagen 
type I and elastin are the unique components for fibrocartilage and elastic cartilage, 
respectively11. Different components make different types of cartilage play different 
roles. The primary mechanical function of fibrocartilage and elastic cartilage is tension, 
but for hyaline cartilage is compression. 
 
A review of 31,516 knee arthroscopies demonstrated that 63% of patients had chondral 
injury12. The pathological changes caused by mechanical injury or degenerative 
pathologies often lead to cartilage dysfunction, further resulting in joint effusion, pain 
and degenerative arthritis13,14. Because cartilage lacks nerves as wells as blood vessels 
and receives its nutrition solely by diffusion15-17, once it is damaged, its self-repair 
ability is negligible18-23. Take the mechanical injuries of articular cartilage as an 
instance; nearly all damages resulting from forces applied to the cartilage and differ in 
the extent and type of tissue damage, leading to various injuries24-26. According to the 
extent of tissue damage, it can be divided into three types27,28: 1) cartilage injury without 
tissue disruption; 2) chondral fissures, flaps or fractures; and 3) osteochondral fractures. 
Each type stimulates a different response and raises a different problem for repair. For 
example, due to the lack of vessels, cartilage damage alone does not cause inflammation; 





inflammatory reactions and the initiation of fracture repair can be triggered because of 
the damage to bone vessels32,33. Cartilage injury is a frequent occurrence and may have 
significant consequences. However, compared with other musculoskeletal injuries, our 
understanding of cartilage injury is still limited. 
 
 
1.2 Cartilage repair and regeneration 
Articular cartilage does not heal itself or only partially under certain biological 
conditions18-23. Numerous clinical and biological attempts have been made to induce a 
significant healing response within mature articular cartilage to reconstruct and repair 
tissue structurally including functionally34,35. Although conservative treatment is of 
great significance for cartilage injury, surgical strategies are also developing and 
innovating. Surgical interventions can be classified into two categories based on the 
involving of active biologics or not36. The commonly used management without active 
biologics participation included: lavage and arthroscopy37, debridement38, abrasion 
chondroplasty39, shaving40,41, laser abrasion/laser chondroplasty42, microfracture 
technique43-45, pride drilling46 and spongialization47. However, the efficacy of these 
clinical methods was controversial. For example, some studies showed that therapeutic 
effects of lavage could persist for a year or more48, but there were also views that 
patients undergoing this therapy did not obtain substantial relief from clinical symptoms, 






Current cartilage restorative techniques with active biologics mainly include fresh 
osteochondral allografts50, cultured chondrocyte implantation51 and osteochondral 
autografts 52. Gross et al.53,54 first attempted to apply fresh osteochondral allografts to 
offset the segmental loss of bone and cartilage in the treatment of osteoarthritis in the 
knee, with promising results. After a 40-month follow-up of 67 patients, Davidson et 
al.55 found that both the International Knee Documentation Committee and SF-36 
scores were significantly improved compared with preoperative values and nearly 
normal International Cartilage Repair Society scores were obtained. A circular socket 
was created first in osteochondral autograft and then harvested using a circular tube 
osteotome which resulted in the limitation of this technique that was the amount of 
available donor material and harvest-related morbidity56-60. Previous cell 
transplantation and current matrix-assisted scaffold techniques provided cell-based 
options for repairing cartilage defects61-63. However, this two-stage cartilage restoration 
technique remains an issue that creates substantial cost and inconvenience in the clinic, 
especially the intervening period of cell culture64,65. In addition, chondrocytes tend to 
dedifferentiate toward a fibroblastic phenotype when cultured in vitro, which was 
presented by Eric et al 66. In their cell culture study, the average collagen type II alpha 
1 (Col2α1) / collagen type I alpha 1 (Col1α1) ratio decreased four orders of magnitude 
(p < 0.0001) over only two passages, indicating a rapid change in phenotype from 
chondrocytic to fibroblastic. Although characterized chondrocyte implantation has been 






In the past two decades, tissue engineering has attempted to use living and functional 
structures to heal damaged or defective structures69. Articular cartilage was the most 
promising first-generation product because of its homogeneous structure, fewer cell 
types and nearly two-dimensional characteristics19. However, the regeneration of 
cartilage, the tissue type of which is simple, was not as successful as predicted and bone 
was likely to be earlier regenerated by tissue engineering despite its more complex 
composition due to the characteristics of cell activity and rich blood vessels.70-72. Only 
a few and low metabolic activity cells exist in the cartilage, which limits the production 
of engineered cartilage for clinical use10,73 (Figure 1, taken from Huey et al. 201219). 
Figure 1. The physiology and putative healing capacity of bone and cartilage. Differences in the 
physiological environment, metabolic rate, and cell composition of bone and cartilage have significant 
effects on the self-repairing ability and tissue engineering potential. Cartilage's hypocellularity and lack 
of nutrient supply preclude healing, while bone integrates rapidly, even with metal. Thus, in contrast to 
bone’s healing ability, cartilage requires more robust exogenous interventions to achieve satisfactory 





Stem cells or terminally differentiated cells which are suitable for cartilage regeneration, 
share the ultimate goal of producing tissue-specific ECM, followed by the consideration 
of the readily available and easily inducible properties74. Mesenchymal stem cells 
(MSCs) have multiple differentiation potential, including chondrocyte, fibro-
chondrocyte and hypertrophic chondrocyte, which is an ideal resource for cartilage 
regeneration75. However, studies indicated that although cell transplantation has shown 
short-term clinical outcomes, such as the enhancement of clinical knee-function scores, 
after two years of follow-up, the results had become worse. The lack of functional 
mechanical properties failed the repair strategy76,77. In addition, the use of scaffolds in 
cartilage regeneration is controversial. In vitro, studies on cartilage regeneration focus 
more on the design of scaffolds aim to better organization and differentiation78,79. 
However, the following challenges, such as the biodegradation rate of scaffolds, by-
products and harsh chemicals involved with scaffold fabrication, encouraged 
researchers to promote the development of scaffold-free technology80. Although 
currently, the cartilage regeneration continues to be elusive, the implementation of new 
approaches has provided the possibility for the development of alternate cartilage 
regeneration technologies, such as the use of various growth factors 81,82. 
 
 
1.3 TGF-β supergene/protein family 
The TGF-β supergene family of proteins is vital for several fundamental biological 





renewed constantly insights into the role of the TGF-β superfamily in cartilage health 
and regeneration opens up new prospects for the treatment of cartilage-related diseases. 
 
1.3.1 Overview of TGF-β supergene/protein family 
The name, TGF-β superfamily, was taken from the first isolated member (TGF-β1)85. 
However, the name is misleading because TGF-β1 was proved to inhibit the 
proliferation of many cell lines and the original "transformation" function may be 
related to matrix production and synergistic effects with other growth factors86,87. The 
members of TGF-β superfamily increased from 17 in 1990 to at least 30 nowadays. 
Based on the sequence similarity and function, they can be divided into two subfamilies, 
which are TGF-β and bone morphogenetic protein (BMP) subfamily88,89. The TGF-β 
subfamily consists of the three TGF-β isoforms, Activin (A and B), Nodals, myostatin 
and Mullerian inhibiting substance, wherein the BMP subfamily BMPs 2, 4-10 and the 
growth and differentiation factors (GDFs) are included. 
 
The cascade reactions in TGF-β signaling are evoked by the binding and assembling 
between ligands and the receptor complex on the cell membrane, including 
serine/threonine kinase types I and II receptors89,90 and the activated type II receptors 
phosphorylate type I receptors91. Type I receptors are also known as activin receptor-
like kinases (ALK) and seven types have been found so far92. ALK 1, 2 and 3 are bound 
with BMPs, while ALK 4, 5 and 7 are bound with TGF-βs93. The phosphorylation not 





mediators, the receptor-regulated SMAD proteins (R‐SMADs)94. The traditional view 
of TGF-β superfamily signaling for BMPs is through R‐SMADs 1, 5 and 8, while the 
members of the TGF-β subfamily transduce signals through R‐SMADs 2 and 393. Upon 
receptor‐mediated phosphorylation, the specific R-SMADs then form heteromeric 
complexes with SMAD 4, a common intracellular mediator shared by the entire TGF-
β superfamily95. The complexes are translocated into the nucleus, induce the 
transcriptional responses combining with other transcription factors91, which is thought 
to be the canonical signaling pathway. The SMADs 6 and 7 (I-SMADs) act as inhibitors 
in the BMPs and TGF-βs signaling cascade91. In addition, BMPs/TGF-βs signals can 
also be transmitted through non-canonical, SMAD-independent avenues, the 
mammalian target of rapamycin (mTOR) pathways and etc96,97. 
 
1.3.2 TGF-βs/BMPs signaling in cartilage development and maintenance 
TGF-βs play a vital role during the entire differentiation progress, including the 
regulation of condensation, proliferation, terminal differentiation and 
maintenance92,98,99. A large amount of in vitro and in vivo evidence indicated that TGF-
β signaling promotes mesenchymal condensation, joint formation and regulate the 
physiology of postnatal/articular cartilage and growth plate100,101. Shintani et al.102 
proved the TGF-β1 inhibit hypertrophic differentiation in bovine synovial explants and 
other studies also demonstrated that the TGF-β3 arrested the terminal differentiation in 
MSCs chondrogenesis103,104. These data indicated that TGF-βs initiated the chondrocyte 





SMAD 2 and 3, which are mediated by TGF-βs, play distinct roles throughout the entire 
period. SMAD 2 is expressed at a relatively higher level in proliferative and pre-
hypertrophic chondrocytes, whereas SMAD 3 is predominant in pre-hypertrophic and 
hypertrophic chondrocytes105. Depletion of SMAD 3 in chondrocytes resulted in the 
progressive articular cartilage degeneration, which confirmed the significance of 
SMAD 3 in cartilage maintenance105. However, the function of SMAD 2 in cartilage in 
vivo is still unclear. On the one hand, SMAD 3 are directly bound to DNA for 
transcriptional regulation, whereas SMAD 2 first require to interact with SMAD 3 or 
other transcription factors106. SMAD 2 may partially compensate for SMAD 3 in 
preventing chondrocyte terminal differentiate107.  
 
BMPs are active substances derived from bone, which are identified by inducing 
ectopic bone and cartilage formation in vivo108, while the mechanism has been the 
subject of intense research for the last three decades. Derynck et al.109 elucidated the 
framework of BMP signal transduction pathway, enabling researchers to enter the 
molecular era of BMPs-induced cartilage morphogenesis. Other studies have shown 
that BMPs directly regulate chondrocyte-specific genes and transcription factors, 
allowing BMPs to establish connections with chondrogenesis110,111. Additionally, the 
proliferation in the growth plate raised by BMPs was first described by Brunet et al.112 
and the intersection with other pathways was also observed. Among these BMPs, BMP-
2 is the first molecule to be clearly described to induce cartilage and bone formation 





combination of a set of BMP-2108. BMP-7, marketed as osteogenic protein 1 (OP-1), 
was the first growth factor commercialized for the treatment of osteoarthritis, although 
the effort was halted and the ability of OP-1 to repair cartilage is reflected in the 
synthesis of proteoglycans, collagen and hyaluronic acid113. 
 
 
1.4 Muscle tissue in vitro model 
Stem cells are most widely used for tissue regeneration, especially for cartilage 
formation, as they can differentiate into different types of mature cells under 
appropriate conditions114,115. The drawbacks of the autologous stem cells 
transplantation in the clinic have been reviewed above, including the time-consuming 
and the expensive procedure which may not lead to a successful regeneration116,117. As 
such, alternative sources and strategies are needed.  
 
The cartilage, bone and muscle are intimately connected tissue and contribute to the 
coordinated interplay in their development, function and aging93,118,119. Hence, the use 
of tissue instead of isolated cells provides a new option to develop more appropriate 
clinical applications. Skeletal muscle is highly adaptable, which is critical in 
determining the overall health, mobility and athletic performance of an individual. The 
musculoskeletal system can alter fiber size, functional capacity and metabolism in 
response to exercise, injury, illness, including other physiological stimuli119,120. Many 





implant. The muscle tissue model provides a familiar internal milieu and structural 
scaffold for cell survival and in the sense of a clinical application can also lower the 
donor site morbidity121. The muscle tissue graft contains a variety of cells with 
mesenchymal multipotencies, such as satellite cells, muscle-derived MSCs and even 
myoblasts 122-124. In terms of osteogenic regeneration, several studies demonstrated that 
muscle-derived stem cells could differentiate into the osteogenic lineage in vitro and in 
vivo and improve bone healing125,126. Betz et al. attempted to use muscle tissue 
fragments to achieve regeneration in the osteochondral defect127-130. When compared 
with autologous bone transplantation, gene modification of tissue surface cells caused 
by direct contact with gene vectors and subsequent implantation resulted in similar 
biomechanical stability and new bone volume127-130. Li et al.131 identified and 
characterized the chondrogenic progenitor cells in the fascia of postnatal skeletal 
muscle by analyzing the surface markers, proliferation rate and chondrogenic ability. 
Moreover, the application of muscles with fascia in the clinic can make the graft have 
a better fixation. All of these conditions are relevant arguments such that more effort 
has to be invested in determining the benefits in muscle culture combined with the 







1.5 Experiment design, aim and hypotheses 
Figure 2. The outline of in vitro chondrogenesis induction using muscle tissue. Three different growth 
factors from the TGF-β superfamily were used, alone or in combinations to induce chondrogenesis in rat 
abdominal muscle tissue. Concerning the withdrawal study, two modes of stimulation were applied, 
which were a continuous application or a single application for an initial 48h. The detections were 
performed on day 7, 14, and 30, including IHC, histological staining, and qRT-PCR. TGF-β3: 
transforming growth factor-beta 3; BMP-2: bone morphogenetic protein 2; OP-1: osteogenic protein 1. 






1.5.1 Experiment design 
This study attempted to detect the chondrogenic induction capacity of three different 
growth factors from TGF-β superfamily (TGF-β3, BMP-2 and OP-1), alone or in 
different combinations. The experimental substances were fresh rat abdominal muscle 
tissue. To monitor the effect of morphogen presence would have on chondrogenesis, 
the withdrawal study, assessed two modes of stimulation. These were a continuous 
application of relevant morphogens and their combinations for the entire duration of 
the in vitro culture or a single application only for 48h. Results were assessed using 
immunohistochemistry (IHC), histological staining and quantitative reverse-
transcriptase polymerase chain reaction (qRT-PCR). Aggrecan was treated as the target 
antigen in the IHC, as it is a key molecule in chondrogenesis. Alcian blue staining was 
also performed to indicate the presence of proteoglycans. The relative gene expression 
levels were analyzed to assess survival, including vascular endothelial growth factor A 
(VEGF-A) and collagen type IV alpha 1 (Col4α1) and chondrogenesis, including sex-
determining region Y (SRY)-box 9 (SOX9), aggrecan (ACAN) and Col2α1. In addition, 
the relative expressions of collagen type X alpha 1 (Col10α1), Col1α1 and alkaline 
phosphatase (ALP) were also detected to determine what type of cartilage matrix was 
being developed (Figure 2). 
 
1.5.2 Aims and Objectives of the study 
The central aim of the study was to investigate how three specific morphogens (TGF-





inducing this process in muscle tissue when these where either applied alone or in 
different combinations with each other, i.e. BMP-2 + TGF-β3, BMP-2 + OP-1, TGF-β3 
+ OP-1 and BMP-2 + OP-1 + TGF-β3. Additionally, a subsequent aim was to determine 
how long morphogens would need to be active within the culture to maintain a 
chondrogenic response. To this end, the growth factors were applied for either 48h or 
the entire duration of the culture period. Finally, since there were limited studies using 
muscle tissue as the experimental model, the last aim was to validate the survival of 
muscle model in vitro after growth factor application and if this tissue type could be 
used to be transformed into cartilage material.  
 
Objectives: 
1. Chondrogenesis induction by the different morphogens alone or their 
combinations, as well as their application duration, were monitored using IHC 
using aggrecan in conjunction proteoglycan production (alcian blue staining) to 
determine what the type of tissue morphogenesis was taking place.  
2. Gene expression patterns were assessed using qRT-PCR to validate that muscle 
tissue was thriving (VEGF-A). Also, the effect of the various morphogens and 
especially their combinations were evaluated to see what the modulatory or 
synergistic aspect was.  
 





The hypothesis was that a single dose stimulation for 48h would be sufficient to induce 
chondrogenic morphogenesis but cannot maintain it. Through a continuous application 
of the selected morphogens, the chondrogenic response can be maintained. Another 
hypothesis was that the more growth factor involved, the more stable chondrogenesis 
would be triggered. Additionally, muscle models can survive in vitro and are a suitable 







2.1 Acquisition of sample 
Four F-344 adult rats (Charles River Sulzbach, Germany) were killed by an overdose 
of isoflurane (Abbot, Chicago, USA). Tissue harvest procedures were conducted 
according to the rules and regulations of the Animal Protection Laboratory Animal 
Regulations (2013), European Directive 2010/63/EU and approved by the Animal 
ethics research committee (AESC) of the Ludwig Maximillian’s University of Munich 
(LMU), Bavaria, Germany Tierschutzgesetz §1/§4/§17 (https://www.gesetze-im-
internet.de/tierschg/TierSchG.pdf) with respect to animal usage for pure tissue or organ 
harvest only. Under sterile conditions, fresh abdominal muscle tissue slab was excised 
and washed twice in Dulbecco phosphate-buffered saline (PBS; Biochrom GmbH, 
Berlin, Germany). The tissue slab was then immersed in the Alpha medium (Biochrom 
GmbH) supplement with 2% penicillin and streptomycin (P/S, Biochrom GmbH) for 
30 minutes, rinsed briefly again in PBS after which it was placed finally in culture 
medium (Alpha medium, 1% P/S and 0.02 mM/mL L-glutamine, Biochrom GmbH). 
Then using a 4mm biopsy punch (PFM medical, Cologne, Germany), 4mm in diameter 
muscle pieces were harvested from the rectus abdomins muscle slab. In a total of 576 
biopsies were harvested and then placed in 96-well Nunc culture plates (Thermo 








2.2 Tissue culture 
After the 48h recovery period, the medium was replaced by relevant differentiation 
medium, which was taken as day 0 of the culturing process. The differentiate medium 
was the culture medium supplemented with three different growth factors alone or in 
varying combinations: 50 ng/mL Recombinant Rat Bone morphogenetic protein 2 
(BMP-2, CUSABIO, USA), 50 ng/mL Recombinant Transforming Growth Factor Beta 
3 (TGF-β3, Cloud-Clone Corp., USA); 50 ng/mL Recombinant Bone Morphogenetic 
Protein 7 (BMP-7 or OP-1, Cloud-Clone Corp., USA); 50 ng/mL BMP-2 + 50 ng/mL 
TGF-β3; 50 ng/mL BMP-2 + 50 ng/mL OP-1; 50 ng/mL TGF-β3 + 50 ng/mL OP-1; 50 
ng/mL BMP-2 + 50 ng/mL TGF-β3 + 50 ng/mL OP-1. All the differentiation groups 
were compared to control group cultured in culture medium without any growth factors. 
In terms of the withdrawal study, the medium in half experimental groups was replaced 
with the normal culture medium after 48h of their first stimulation of growth factors. 
The medium was changed every two days as required. All samples were cultured at 37℃ 
in a 5% CO2 humidified incubator and harvested on day 7, 14 and 30. Half of the 
samples were harvested and then frozen in the liquid nitrogen (Nliq) immediately. They 
were kept in the -80℃ until used for qRT-PCR. Half of the samples were fixed in 30% 
formalin (Microcos GmbH, Germany) for 24h, dehydrated in a Gewebeprozessor 
Entwässerungsautomat STP 120 unit (Thomas-medical e.U., Maishofen, Austria) and 







2.3 Quantitative reverse transcriptase polymerase chain reaction 
(qRT-PCR) 
In order to obtain more accurate relative gene expression results, pre-experiments and 
corresponding optimization for each step were conducted, including the determination 
of reference genes, reaction volume as well as ratio, gradient tests of optimal 
temperature and substrate concentration. The qBase+ software 
(https://www.qbaseplus.com/) was applied for the normalization. The final results were 
presented in the form of calibrated normalized relative quantities (CNRQ) values and 
analyzed statistically. 
 
2.3.1 Primer design 
PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) was used to find information about 
genes of interest. Search parameters were set in the “Nucleotide” database accordingly 
to gene name with the restriction conditions of species, molecule and organisms limited 
to “Animal”, “mRNA” and “Rattus norvegicus [rodents]”, respectively. Then the 
coding sequences (CDS) were saved through FASTA interface (FASTA was a suite of 
programs for searching nucleotide or protein databases with a query sequence), so 
sequence coding for amino acids in the protein of genes of interest was obtained. 
 
Primers were designed and evaluated utilizing IDT website (https://eu.idtdna.com/site). 
CDS were assessed for viable primers using PrimerQuest Tool. After entering the 





settings were applied:  
1) The result to return was 50.  
2) The Primer Melting Temperature (Tm) containing the minimum, optimum and 
maximum melting temperatures (Celsius) for a primer oligo were set as 59, 60 and 61. 
3) The primer GC% containing minimum, optimum and maximum percentage of Gs 
and Cs in any primer generated by PrimerQuest were set as 47, 50 and 53. 
4) The primer sizes containing the minimum, optimum and maximum size of the 
desired primer(s) were set as 16, 18 and 20. 
5) The amplicon sizes containing the minimum, optimum and maximum size for the 
desired amplicon were set as 150, 160 and 210.  
Generated possible primers were subsequently screened using the OligoAnalyzer Tool 
to select the best primers that would deliver specific amplification of the desired gene(s) 
region without generating artifact amplifications. The following Gibbs standard free-
energy change (ΔG) scores were looked for in generated primers: a hairpin structure 
ΔG > -2 and a self-dimer structure ΔG > -5, with the pairs of both dimers < 3. Also, 
hetero-dimer non-specific amplifications between forward and reverse primers for a 
gene required limited to below 3 with ΔG > -6.  
 
Primers were scaled from best to worst accordingly. After a temperature gradient 
optimization step using the best possible primer pair, providing information about the 
optimum amplification temperatures to use during the qRT-PCR, the relevant amplified 





Germany) and primer specificity confirmed by Sanger sequencing (GATC Biotech, 
Cologne, Germany) in conjunction with nucleotide mega-blast analysis 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch)132,133. 
 
2.3.2 The determination of the optimal reference genes by GeNorm 
To optimize the normalization, geNorm (http://medgen.ugent.be/wjvdesomp/genorm/) 
was used to find the most stable reference genes and the number required to generate 
accurate gene expression data134. The primers of eight candidate genes were designed 
according to the Primer design method (Section 2.3.1) TATA-binding protein (TBP), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), RNA polymerase II subunit e 
(POLR2e), ribosomal protein lateral stalk subunit P0 (RPLP0), succinate 
dehydrogenase complex flavoprotein sub-unit A (SDHA), ribosomal protein L13α 
(RPL13α), RNA-28S ribosomal 4 (RNA28S4) and actin beta (ACTB) (Table 1) were 
tested. After all the samples were harvested, the relative gene expressions of eight 
candidate genes in all samples were obtained by qRT-PCR (mean of duplicate 
detections) in the form of the cycle threshold Value (Ct; more correctly called cycle 
quantification, Cq). The delta-Cq value was calculated based on the original Cq value 
of each gene according to the formula: 
∆Cq = 2('()*+,'(-.)/01) 
After the expression data matrix was loaded into GeNorm, two charts were generated. 
The first graph presented the genes, ranked, according to increasing expression stability, 





indicated the results of the pairwise variation (V) between two sequential normalization 
factors containing an increasing number of genes revealing the optimal quantity of the 





Table 1. Gene primers for Rattus norvegicus with accession number and sequence  
Gene  Accession Number  5’ – 3’ sequence  3’- 5’ sequence  
Reference genes 
TBP  BC081939.1  TAACCCAGAAAGTCGAAGAC  CCGTAAGGCATCATTGGA  
GAPDH  BC083511.1  CATGGGTGTGAACCATGA  TGTCATGGATGACCTTGG  
POLR2e  BC158787.1  GACCATCAAGGTGTACTGC  CAGCTCCTGCTGTAGAAAC  
RPLP0  BC001834.2  CAACCCAGCTCTGGAGA  CAGCTGGCACCTTATTGG  
SDHA  NM_130428.1  GCGGTATGAGACCAGTTATT  CCTGGCAAGGTAAACCAG  
RPL13α  NM_173340.2  TTTCTCCGAAAGCGGATG  AGGGATCCCATCCAACA  
ACTB  NM_031144.3  AGCTATGAGCTGCCTGA  GGCAGTAATCTCCTTCTGC  
RNA28S4  NR_145822.1  GCGGCCAAGCGTTCATA  CCTGTCTCACGACGGTCTAA   
    
Genes of interest 
Col1α1 NM_053304.1 GGTGACAGAGGCATAAAGG AGACCGTTGAGTCCATCT 
Col2α1 NM_012929.1  ATCCAGGGCTCCAATGA TCTTCTGGAGTGCGGAA 
Col4α1 NM_001135009.1  CTGGGAATCCCGGACTT GGGATCTCCCTTCATTCCT 
Col10α1 XM_001053056.7 CCAGGTCTCAATGGTCCTA ATTTCCTCACGGACCTGT 
ACAN NM_022190.1  CAAGTGGAGCCGTGTTT  TTTAGGTCTTGGAAGCGAG 
ALP NM_013059.2 CGACAGCAAGCCCAAG  AGACGCCCATACCATCT  
SOX9 NM_080403.1 CCAGAGAACGCACATCAAG ATACTGATGTGGCTGGTGG 
VEGF-A  NM_001317043.1  CTACCAGCGCAGCTATTG GATCCGCATGATCTGCATAG 
TBP: TATA-binding protein, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, POLR2e: RNA polymerase II subunit e, RPLP0: Ribosomal protein 
lateral stalk subunit P0, SDHA: Succinate dehydrogenase complex flavoprotein sub-unit A, ROL13α: Ribosomal protein L13α, ACTB: Actin beta, 
RNA28S4: RNA 28S ribosomal 4, Col1α1: Collagen Type I Alpha 1, Col2α1: Collagen Type II Alpha 1, Col4α1: Collagen Type IV Alpha 1, Col10α1: 
Collagen Type X Alpha 1, ACAN: Aggrecan, ALP: Alkaline phosphates, SOX9: SRY (Sex Determining Region Y)-Box 9, VEGF-A: Vascular endothelial 





participation of more reference genes was redundant.  
 
2.3.3 qRT-PCR 
The whole qRT-PCR process was compliant with the Minimum Information for 
Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines135. The 
primers of eight genes of interest were designed according to the primer design method 
described in Section 2.3.1. Genes selected for the study were: VEGF-A, Col4α1, SOX9, 
ACAN, Col2α1, Col10α1, Col1α1 and ALP (Table 1). Harvested specimens designated 
for gene expression analysis were taken from -80℃ and under sterile RNase-free 
conditions homogenized into a fine powder using Nliq in conjunction with mortar and 
pestle. The modified RNA was then extracted using the RNeasy® Fibrous Tissue Mini 
Kit (Qiagen, Hilden, Germany), with the specific steps shown in Figure 3. The quality 
and concentration of RNA were detected using NanoDropTM Lite (Thermo Scientific) 
by spectrophotometry. Total RNA was kept at -80 ℃ until used. RNA was reverse 
transcribed using the QuantiTect Reverse Transcription cDNA Synthesis Kit (Qiagen). 
cDNA was kept at -20 ℃ until used. qPCR was performed on a LightCycler® 96 
Instrument (Roche, Basel, Switzerland) in duplicate using 2x FastStart Essential DNA 
Green Master (Roche). The process of thermocycling included a 2 minutes denaturation 
step at 94 °C, 40 cycles containing a denaturation, annealing and extension step set at 
95 °C for 10s, 60 °C for 15s and 72 °C for 30s, respectively; and a final extension at 
72 °C for 5 minutes. The total volume of each reaction was 10μL and the ratio of each 





primer (10μmol/L), 0.6μL reverse primer (10μmol/L), 2μL cDNA (5ng/μL) and 1.8μL 
Figure 3. Flowchart of modified RNA extraction using a RNeasy® Fibrous Tissue Mini Kit (Qiagen, 
Hilden, Germany). QIAzol was used to lyse cells, and RNA integrity was maintained. Chloroform was 
added and centrifuged. The solution was divided into the aqueous phase, interphase, and phenol-
chloroform phase. RNA exists in the aqueous sample layer. After washing with RW1 and RPE, DNA and 





RNase-free water. The LightCycler® software (Roche) was used to generate Cq values 
of each gene in each sample.  
 
To generate the CNRQ data, qBase+ was used utilized. Groups were normalized to the 
pre-determined reference genes, including fresh muscle tissue that reflects the base-line 
in CNRQ graphs.  
 
 
2.4 Histologic analyses (Alcian blue) 
The sample preparation process was described in section 2.2 and 2μm-thick paraffin 
wax sections of specimens were mounted on Superfrost glass slides (Menzel, 
Braunschweig, Germany). Alcian blue staining was used to detect the presence of 
glycosaminoglycans in cartilages and other body structure; hence, the detection of 
mucopolysaccharides was accomplished by using the alcian blue- nuclear red stain kit. 
Briefly, sections were de-waxed prior to staining by first placing the section at 60 °C 
for 1h followed by immersion into xylene (SAV Liquid Production GmbH, Flintsbach 
am Inn, Germany), twice, for 10 and 5 minutes each. Re-hydration of the sections was 
achieved by decreasing ethanol concentrations (100%, 100%, 96%, 70% ethanol; each 
step 5 minutes; Apotheke Großhadern, Munich, Germany) into deionized (DI) water. 
After having been left in DI for 2 minutes sections were transferred to 3% acetic acid 
(Morphisto- Evolutionsforschung und Anwendung GmbH, Frankfurt am Main, 
Germany) for 3 minutes followed by Alcian Blue staining at pH 2.5 (Morphisto- 





transfer back to 3% acetic acid for 3 minutes, washed briefly for 5 min in DI water and 
subsequently counterstained in nuclear fast red solution (Morphisto- 
Evolutionsforschung und Anwendung GmbH) for 5 minutes. Sections were then briefly 
agitated in DI water for 1 minute and dehydrated via ascending concentrations of 
ethanol into xylene followed by cover-slip mounting using EUKITT resinous mounting 
medium (O. Kindler GmbH, Bobingen, Germany)136. 
 
Histological sections were analyzed and images were captured using a PreciPoint M8 
microscope (PreciPoint, Freising, Germany) with integrated Viewpoint software 
(PreciPoint). Histomorphometric analysis was performed using the Image-Pro Plus 
software (version 6.0, Meyer Instruments, Inc.). The total area of the tissue section and 
the positive area (area stained blue) were measured and the ratios between them 
(positive area/ total area) were considered as the original semi-quantitative analysis data 
of each section 132,133. 
 
 
2.5 Immunohistochemical analyses 
The detection of aggrecan antigen, one of the most abundant macromolecules of 
articular cartilage, was accomplished through IHC. Washing buffer (WB) was prepared 
in advance, which was usually a mixture of 2.5L PBS and 2.5mL Tween (Merck 
Schuchardt OHG, Hochenbrunn, Germany). Prior to IHC, slides with sections were 





Specimens were then re-hydrated through ascending levels of (100%, 100%, 96% and 
70% ethanol; 5min each step) into DI water. Sections were placed into 3% H2O2 for 5 
min, washed by the WB and then placed in the DI water.  
 
Rodent Decloaker (ZYTOMED SYSTEMS GmbH, Berlin, Germany) was diluted by 
DI water and concentrated at a ratio of 1:10 to make the antigen retrieval buffer. The 
appropriate buffer was added to the etui holding the sections and then put into a pressure 
cooker for antigen retrieval. After 15 minutes slides were left to cool down for about 30 
minutes within a deactivated pressure cooker after which they were removed from the 
etui and placed at room temperature for another 15 minutes. 
 
All incubations in the staining process were conducted in a humidified chamber to avoid 
drying of the sections. Dilutions of the primary antibody in antibody diluent 
(ZYTOMED SYSTEMS GmbH) were determined by testing a range, which was 1:150 
for aggrecan (Biorbyt Ltd., Cambridge, United Kingdom). Slides were first for 2 
minutes in WB. Two drops of Rodent block R (ZYTOMED SYSTEMS GmbH) were 
dropped onto the tissue sections and then washed for 2 minutes in WB twice. The 
primary antibody was then applied and left at room temperate for 1 hour at the room 
temperature. After primary antibody application the sections washed three times, 2 
minutes each, WB after which three drops of Rabbit-on-Rodent HRP-Polymer 
(ZYTOMED SYSTEMS GmbH) were applied and incubated for 20 minutes after 





chromogen and buffer (ZYTOMED SYSTEMS GmbH) were then applied to the slides 
(3 drops) and incubated for 10 minutes at room temperature. The slides were briefly 
rinsed with DI water.  
 
Counterstaining was achieved by using haematoxylon for 30 seconds, after which slides 
were rinsed under running tap water for 30 minutes after which they were then 
dehydration through ascending grades of alcohol into xylene. Finally, sections were 
mounted using a cover-slip and EUKITT resinous mounting medium. 
 
Images were captured and digitalized using a PreciPoint M8 research microscope and 
Viewpoint software. Semi-quantitative histomorphometrical analysis was performed 
using Image-Pro Plus software. The absorbance value of the incident light in the blank 
of the tissue piece was calibrated firstly and then the area of total tissue and the 
integrated optical density value (IOD) of the positive area were measured. Then the 
mean optical density value (MOD) of the positive area was calculated (MOD= IOD/ 
area), which quantify the intensity of immunostaining137. 
 
 
2.6 Statistical analysis 
Statistical evaluations were performed on qRT-PCR and histomorphometric data of 
both histological and IHC material. GraphPad Prism (version 7.0, GraphPad Software, 





Dunnet’s test was used to determine the statistical differences between different 
experimental and corresponding control groups. A one-way ANOVA with Tukey's 
multiple comparisons test was used to compare the mean of each group with the mean 
of every other group. A two-way ANOVA with multiple comparisons was mainly used 
to compare the difference between each experimental group with a single and 
continuous application at the same time point and the changes of each experimental 







3.1 Gene expression 
Eight candidate reference genes were assessed in all samples using qRT-PCR where 
finally, TBP, GAPDH, POLR2e, RPLP0, SDHA and RPL13α were determined as being 
the most suitable reference gene set to generate accurate relative gene expression data 
(Figure 4). Eight target genes were also detected in all samples and normalized to the 
above 6 reference genes using qBase+ software including a pure endogenous muscle 
control group that was fresh. The results were presented as the mean CNRQ values and 
analyzed using GraphPad Prism software. The results were mainly compared between 
the experimental group and the corresponding control group, the continuous application 




Figure 4. The determination of the optimal reference genes by GeNorm. (A) Genes ranked according to 
increasing expression stability, with the most stable genes (POLR2e and RPL13α) beginning from the right of 
the chart. (B). Results of the pairwise variation (V) between two sequential normalization factors containing 
an increasing number of genes revealing the optimal quantity of the reference gene. The lowest V value (V5/6) 
was set as the cut-off value below which participation of more reference genes was redundant. Finally, TBP, 







ACAN was increased significantly in all treatment groups in relation to controls when 
morphogens and their different combination were applied continuously for the 7, 14, 
30 days in vitro culturing period. On day 7, the relative expression level in the group 
treated with BMP-2 only showed a significantly greater expression than all other 
treatment modalities at that time point. By day 14, this trend was then replaced by the 
TGF-β3 + OP-1 followed by the BMP-2 + TGF-β3 + OP-1 group at day 30. There were 
no significant changes in the relative expression levels of ACAN in the control group 
over time. The relative expression levels in BMP-2 and BMP-2 + TGF-β3 continuous 
treatment groups decreased sharply from day 7. ACAN peak values were found in TGF-
β3 alone, OP-1 alone, BMP-2 + OP-1 and TGF-β3 + OP-1 groups on day 14 which 
remained then stable throughout the culture period. No significant change of ACAN was 
found in the BMP-2 + TGF-β3 + OP-1 group from day 7 to 14, but only then there was 
an increase and the mean value exceeded other groups on day 30 (Figure 5, Appendix 
A). 
 
At all the three time points, the relative expression levels of ACAN in continuous 
morphogen application groups were significantly higher than that in the corresponding 
treatment groups that had only been applied for 48h. Although there were differences 
in the expression patterns of ACAN when morphogens and their combinations were 
applied initially for 48h, none of the experimental groups were able to maintain the 





found compared to the controls. The only notable difference was found in 48h OP-1, 
48h BMP-2 + TGF-β3 and 48h BMP-2 + OP-1 groups in which ACAN was significantly 
decreased by day 14, followed by a significant increase by day 30 that was almost equal 
to other treatment parameters (Figure 5, Appendix B). 
 
3.1.2 SOX9 
The relative expression levels of SOX9 in nearly all experimental groups were 
stimulated continuously for 7, 14 and 30 days in vitro culturing period were 
significantly higher than that in the corresponding control group, except the BMP-2 and 
BMP-2 + TGF-β3 + OP-1 groups on day 14. Similar to the ACAN, the highest relative 
expression level of SOX9 were BMP-2, TGF-β3 + OP-1 and BMP-2 + TGF-β3 + OP-1 
groups on day 7, 14, 30, respectively. The relative expression level in the BMP-2 
continuous treatment groups dropped rapidly on day 14 and continued to decrease at a 
lower rate, which is similar to the time pattern in ACAN expression. TGF-β3 alone and 
TGF-β3 + OP-1 continuous treatment groups showed an upward trend from day 7 to 14 
but without statistical significance. The other continuous stimulation experimental 
groups kept stable after reaching their peak on day 7 (Figure 6, Appendix A). 
 
At all the three time points, the relative expression levels of SOX9 in continuous 
morphogen application groups were significantly higher than in the corresponding 
treatment groups that had only been applied for 48h, except for the BMP-2 alone and 





SOX9 on day 30 became negative in all single stimulation groups. 48h application of 
BMP-2 + TGF-β3 resulted in the consistently and significantly lower relative expression 
levels than that in the corresponding control group on day 7 and 14. The single dose of 
OP-1 group showed significantly lower results in relation to the corresponding control 
group only on day 7, while TGF-β3 + OP-1 group was lower on 14. The other single 
stimulation groups did not show any difference from the corresponding control group 
at three time points (Figure 6, Appendix B). 
 
3.1.3 Col2α1 
Col2α1 was increased significantly in all treatment groups in relation to controls when 
morphogens and their different combination were applied continuously for the 7 and 14 
days in vitro culturing period, except the TGF-β3 group on day 7. On day 7, the relative 
expression level in the group treated with BMP-2 only showed a significantly greater 
expression than all other treatment modalities at that time point which was similar to 
the results of ACAN and Sox9, but this trend was then replaced by the TGF-β3 + OP-1 
group on day 14. On day 30, the mRNA of Col2α1 could not be detected in some 
samples received the continuous stimulations using qRT-PCR, resulting in the data 
volume of TGF-β3 and BMP-2 + OP-1 groups could not meet the requirements of the 
statistical analysis. Most of the groups stimulated continuously showed a decreasing or 
unchanged trend over time from day 7, but BMP-2 + TGF-β3 group reached the peak 
on day 14. Additionally, the relative expression levels of Col2α1 in the group applied 





pattern of ACAN and SOX9 (Figure 7, Appendix A). 
 
The mRNA of Col2α1 could be detected in all groups applied the proteins for 48h, alone 
or in varying combinations. At all the three time points, the relative expression levels 
of Col2α1 in continuous morphogen application groups were significantly higher than 
that in the corresponding treatment groups that had only been applied for 48h. The 
results were all negative in groups applied once on day 14. On day 30, the relative 
expression levels in groups applied BMP-2 + OP-1 and BMP-2 + TGF-β3 + OP-1for 
48h were up-regulated and significantly higher than that in the corresponding control 
group (Figure 7, Appendix B). 
 
3.1.4 Col1α1 
At all the three time points, the relative expression levels of Col1α1 maintained positive 
only in control group and the group applied TGF-β3 for 48h. Except the above two 
groups, the relative expression levels of Col1α1 in the other groups reached their bottom 
on day 7, no matter they received a single or continuous stimulation. Thereafter, all 
groups presented an upward trend and reached the highest value on day 30 and became 
positive except the group applied BMP-2 + OP-1 continuously. After continuous 
stimulation, the relative expression levels of Col1α1 in most experimental groups were 
significantly lower than that in the corresponding control group, except the OP-1 group 
on day14, TGF-β3 + OP-1 and BMP-2 + TGF-β3 + OP-1 groups on day 30 showed no 





points, the relative expression levels of Col1α1 in continuous morphogen application 
groups were significantly lower than that in the corresponding treatment groups that 
had only been applied for 48h, which was contrary to the results of ACAN and SOX9 
(Figure 8, Appendix A and B). 
 
3.1.5 Col10α1 
Although the total mRNA was extracted from six samples in each experimental group 
stimulated continuously, but the expression of Col10α1 could not detected resulting that 
the data size did not meet the statistical requirements for analyses. Therefore, more 
information about Col10α1 could not be obtained in groups which were applied the 
growth factors continuously. 
 
The relative expression of Col10α1 also could not be detected in the groups applied 
TGF-β3 + OP-1 or BMP-2 + TGF-β3 + OP-1 for 48h on day 7; however, it became 
measurable in these two groups on day 14 and 30. Nevertheless, all available data 
obtained from the single stimulation groups was negative at any time point, except the 
BMP-2 + TGF-β3 + OP-1 group on day 30. There was no difference in other valid data 
when compared with the corresponding control group at all three time points, except 
the group applied OP-1 once on day 7 and the group applied BMP-2 + OP-1 once on 








The relative expression level of ALP in group applied BMP-2 alone continuously on 
day 7 was the only positive data in all groups and at all time points. The other groups 
stimulated continuously showed a decreasing trend from the beginning of the detection 
time point. On day 7 and 14, the relative expression level of ALP in groups applied 
continuously were higher than that in corresponding groups stimulated for 48h, but the 
results were reversed in all the experimental groups with BMP-2 participation on day 
30 (Figure 10, Appendix A and B). 
 
3.1.7 Col1α1, Col2α1 and ALP 
The relative expression levels of Col1α1, Col2α1 and ALP in the control group and the 
experimental groups applied the same morphogens continuously for 7, 14 and 30 days 
were compared base on the time point. In the control group, the order of relative 
expression levels of these three genes from high to low is Col1α1, Col2α1 and ALP at 
all time points. Col2α1 was expressed significantly stronger than the other two genes 
in all experimental group on day 7 and 14; however, the difference between Col1α1 and 
Col2α1 in the groups applied BMP-2 alone, BMP-2 + TGF-β3 and BMP-2 + TGF-β3 + 
OP-1 continuously became insignificant on day 30. The relative expression levels of 
Col2α1 maintained dominant from day 7 to 30 in groups applied OP-1 and TGF-β3 + 
OP-1 continuously, while the Col1α1 became the greatest one in the other groups on 
day 30. The relative expression level of ALP shared the similar time pattern with Col2α1 





negative and keep the lowest relative expression level at most time points (Figure 11). 
 
3.1.8 VEGF-A 
Most experimental groups stimulated continuously showed the significantly higher 
relative expression level of VEGF-A than that in the corresponding control group on 
day 7, expect the group applied BMP-2 alone continuously. By day 14, only the groups 
stimulated by TGF-β3 alone, BMP-2 + TGF-β3 and BMP-2 + TGF-β3 + OP-1 
continuously were found the significantly higher relative expression levels than that of 
the control. The values in all experimental groups on day 30 were either not different 
from that of the control group or significantly lower (Figure 12, Appendix A). 
 
At all the three time points, the relative expression levels of VEGF-A in continuous 
morphogen application groups were significantly higher than that in the corresponding 
treatment groups that had only been applied for 48h, except for the BMP-2 alone treated 
groups on day 7. The relative expression levels of VEGF-A in all experimental groups 
stimulated for 48h showed no difference with the control group on day 7. By day 14, 
among all the single dose experimental groups, only the groups applied OP-1 and TGF-
β3 + OP-1 showed positive value though lower than that in the corresponding control 









The relative expression levels of Col4α1 in the control group decreased continuously 
and became negative on day 30, while the value of the other continuous stimulation 
groups maintained positive during the entire culture. The values in most experimental 
groups applied morphogens continuously showed a downward trend from day 7, except 
OP-1 alone treated group decreased from day 14 and BMP-2 + TGF-β3 treated group 
increased significantly after reaching the bottom on day 14. The highest relative 
expression level of Col4α1 on day 7 and 14 was found in the group applied BMP-2 + 
TGF-β3 + OP-1 continuously (Figure 13, Appendix A). 
 
The relative expression levels of Col4α1 in continuous morphogen application groups 
on day 7 were higher than that in the corresponding treatment groups that had only been 
applied for 48h and significant difference was found in most experimental groups 
except the TGF-β3 alone and OP-1 alone treated groups (Figure 13, Appendix B). 
 
 
3.2 Histomorphometric assessment 
3.2.1 Alcian Blue staining 
Alcian blue would show the presence of glycosaminoglycans in cartilages and other 
body structures and the positive area was stained in blue. The positive area was found 
in nearly all the groups at all time points, no matter the control group or experimental 





intercellular space of muscle cells or near the fascia (Figure 14). 
 
According to the semi-quantitative analysis of alcian blue staining, the positive area 
ratios were lower than 5% at three time points, although it presented an increasing trend. 
The positive area ratio in the experimental groups stimulated continuously significantly 
higher than that in the corresponding control group at all time points, except BMP-2 + 
TGF-β3 and BMP-2 + TGF-β3 + OP-1 treated groups on day 7 and TGF-β3 treated group 
on day 14. The highest positive area ratio was found in the group treated BMP-2 + OP-
1 continuously on day 14. The comparison between the experimental groups applied 
the same morphogens continuously and for only 48h showed the significant difference 
in BMP-2 + OP-1 treated groups on day 7 and most experimental groups on day 14 and 
30 (Figure 15). 
 
3.2.2 Aggrecan Immunohistochemistry  
By means of IHC, in which aggrecan was treated as the antigen, the green area indicated 
the positive antigen-antibody interactions. The positive area was detected in nearly all 
the groups at all time points, no matter the control group or experimental groups 
stimulated continuously or only for 48h, although the positive reaction was very weak 
in the control group and the single stimulation experimental groups. The positive areas 
appeared in any part of the sections, including the muscle cells, the intercellular space 
and the fascia (Figure 14). 
 





application groups were significantly higher than that in the corresponding groups 
stimulated for 48h at all time points. The group applied BMP-2 continuously showed 
the highest MOD among all groups on day 14. Similar to the time pattern of the relative 
expression levels of chondrogenesis-related genes in 7 to 14 days, the MOD value of in 
the group applied BMP-2 continuously declined sharply after reaching the peak on day 
14. Additionally, the strongest positive reaction on day 30 was found in the BMP-2 + 
TGF-β3 continuous group, although there was not significantly different from the group 








Figure 5. The analyses of the relative expression levels of aggrecan (ACAN). The results were presented as 
calibrated normalized relative quantity (CNRQ). (A) Comparisons between each experimental group under 
different stimulation modes and the corresponding control group on day 7, 14 and 30 using one-way ANOVA. 
(B) Comparisons between the experimental groups with single and continuous application of the same 
combination of growth factors on day 7, 14 and 30 using two-way ANOVA. Con.= control group, B= BMP-2 
treated group, T= TGF-β3 treated group, O= OP-1 treated group, B+T = BMP-2 + TGF-β3 treated group, 
B+O=BMP-2 + OP-1 treated group, T+O= TGF-β3 + OP-1 treated group, B+T+O= BMP-2 + TGF-β3 + OP-1 








Figure 6. The analyses of the relative expression levels of SRY (Sex Determining Region Y)-
Box 9 (SOX9). The results were presented as calibrated normalized relative quantity (CNRQ). 
(A) Comparisons between each experimental group under different stimulation modes and the 
corresponding control group on day 7, 14 and 30 using one-way ANOVA. (B) Comparisons 
between the experimental groups with single and continuous application of the same 
combination of growth factors on day 7, 14 and 30 using two-way ANOVA. We defined 








Figure 7. The analyses of the relative expression levels of collagen type II alpha 1 (Col2α1). 
The results were presented as calibrated normalized relative quantity (CNRQ). (A) 
Comparisons between each experimental group under different stimulation modes and the 
corresponding control group on day 7, 14 and 30 using one-way ANOVA. (B) Comparisons 
between the experimental groups with single and continuous application of the same 
combination of growth factors on day 7, 14 and 30 using two-way ANOVA. The data volume 
in the experimental groups applied TGF-β3 and BMP-2 + OP-1 continuously on day 30 could 
not meet the requirements of the statistical analysis. NA= not available. We defined p<0.05 as 







Figure 8. The analyses of the relative expression levels of collagen type I alpha 1 (Col1α1). 
The results were presented as calibrated normalized relative quantity (CNRQ). (A) 
Comparisons between each experimental group under different stimulation modes and the 
corresponding control group on day 7, 14 and 30 using one-way ANOVA. (B) Comparisons 
between the experimental groups with single and continuous application of the same 
combination of growth factors on day 7, 14 and 30 using two-way ANOVA. We defined 








Figure 9. The analyses of the relative expression levels of collagen type X alpha 1 (Col10α1). The results 
were presented as calibrated normalized relative quantity (CNRQ). (A) Comparisons between each 
experimental group under a single stimulation and the corresponding control group on day 7, 14 and 30 
using one-way ANOVA. (B) Changes in the relative expression levels of Col10α1 in the experimental 
groups with a single application of the same combination of growth factors on day 7, 14 and 30 using 
one-way ANOVA. The data volume in all the experimental groups stimulated continuously could not 
meet the requirements of the statistical analysis. The data volume in the experimental groups applied 
TGF-β3 + OP-1 and BMP-2 + TGF-β3 + OP-1 for 48h could not meet the requirements of the statistical 
analysis on day 7. NA= not available. We defined p<0.05 as a statistically significant difference. * 







Figure 10. The analyses of the relative expression levels of alkaline phosphatase (ALP). The 
results were presented as calibrated normalized relative quantity (CNRQ). (A) Comparisons 
between each experimental group under different stimulation modes and the corresponding 
control group on day 7, 14 and 30 using one-way ANOVA. (B) Comparisons between the 
experimental groups with single and continuous application of the same combination of 
growth factors on day 7, 14 and 30 using two-way ANOVA. We defined p<0.05 as a 








Figure 11. The analyses of the relative expression levels of Col1α1, Col2α1 and ALP in the group applied 
the same morphogens continuously at all the time points. The data volume of Col2α1 in TGF-β3 and 
BMP-2 + OP-1 group on day 30 could not meet the requirements of the statistical analysis. B= BMP-2 
treated group, T= TGF-β3 treated group, O= OP-1 treated group, B+T = BMP-2 + TGF-β3 treated group, 
B+O=BMP-2 + OP-1 treated group, T+O= TGF-β3 + OP-1 treated group, B+T+O= BMP-2 + TGF-β3 + 







Figure 12. The analyses of the relative expression levels of vascular endothelial growth factor 
A (VEGF-A). The results were presented as calibrated normalized relative quantity (CNRQ). 
(A) Comparisons between each experimental group under different stimulation modes and the 
corresponding control group on day 7, 14 and 30 using one-way ANOVA. (B) Comparisons 
between the experimental groups with single and continuous application of the same 
combination of growth factors on day 7, 14 and 30 using two-way ANOVA. We defined 








Figure 13. The analyses of the relative expression levels of collagen type IV alpha 1 (Col4α1). 
The results were presented as calibrated normalized relative quantity (CNRQ). (A) 
Comparisons between each experimental group under different stimulation modes and the 
corresponding control group on day 7, 14 and 30 using one-way ANOVA. (B) Comparisons 
between the experimental groups with single and continuous application of the same 
combination of growth factors on day 7, 14 and 30 using two-way ANOVA. We defined 












Figure 14. The staining results of the control group and the experimental groups stimulated continuously 
on day 30, including alcian blue staining and immunohistochemistry (IHC). (A1-A8). These figures 
represented the alcian blue staining results of control group and the experimental groups applied BMP-
2 alone, TGF-β3 alone, OP-1 alone, BMP-2 + TGF-β3, BMP-2 + OP-1, TGF-β3 + OP-1 and BMP-2 + 
TGF-β3 + OP-1continuously, respectively. The color of positive reaction in alcian blue was blue which 
indicated the deposition of acidic polysaccharides. (B1-B8). These figures represented the aggrecan IHC 
results of control group and the experimental groups applied BMP-2 alone, TGF-β3 alone, OP-1 alone, 
BMP-2 + TGF-β3, BMP-2 + OP-1, TGF-β3 + OP-1 and BMP-2 + TGF-β3 + OP-1continuously, 
respectively. The target antigen in IHC was aggrecan. The color of the positive antigen–antibody 







Figure 15. The semi-quantitative analysis of alcian blue staining. The results were presented 
as positive area ratio (%). (A) Comparisons between each experimental group under different 
stimulation modes and the corresponding control group on day 7, 14 and 30 using one-way 
ANOVA. (B) Comparisons between the experimental groups with single and continuous 
application of the same combination of growth factors on day 7, 14 and 30 using two-way 
ANOVA. We defined p<0.05 as a statistically significant difference. * p<0.05, ** p<0.01, *** 







Figure 16. The semi-quantitative analysis results of immunohistochemistry (IHC). The results were 
presented as optical density value (MOD). The target antigen in IHC was aggrecan. (A) Comparisons 
between each experimental group under different stimulation modes and the corresponding control 
group on day 7, 14 and 30 using one-way ANOVA. (B) Comparisons between the experimental groups 
with single and continuous application of the same combination of growth factors on day 7, 14 and 30 
using two-way ANOVA. We defined p<0.05 as a statistically significant difference. * p<0.05, ** 






4.1 The muscle tissue model 
The study of morphogens/proteins/ligands and their effect on biological systems has 
historically always been performed on isolated stem or differentiated cells in vitro1,138-
140. Cicione et al.141, for example, investigated the capacity of BMP-2, OP-1, and TGF-
β3 and their chondrogenic differentiation effect on MSCs in vitro under normoxic 
conditions, whilst Gozo et al.142 attempted to represent the Forkhead box protein C2-
mediated regeneration and osteogenesis in muscle tissue in vitro by utilizing C2C12 
myoblasts. Whilst cell-based research has shed much light on the signal transduction 
cascade and how morphogens affect the cell differentiation behavior, how accurate 
these interpretations are in relation to a tissue, which actually makes up an organism, 
remains questionable. Tissues are not entirely composed of a single cell type but a 
combination of different cells interacting with each other to produce a specific tissue 
wide response. If now an extracellular signal is presented, single cell response studies 
can only provide a basic single response yet do not reflect the response of the 
complexities of tissue since many types of cells and the cell-specific extracellular 
matrices are involved generating a cascading and often varying response123,143,144. The 
benefits of using tissue in research and for regenerative procedures remains far more 
beneficial than single stem cells. Studies have shown that stem cells containing in the 
muscle tissue can differentiate into several lineages in vitro and in vivo125,126. Moreover, 
it was shown that cells cultured in vitro after isolation from their natural environment 





blocks were lacking145,146, while tissue in vitro cultures might release the critical 
components such as extra glucose and proteins147-149, to assists in establishing a new 
homeostasis. Furthermore, the realization of tissue based regeneration will have clinical 
significance, which was to solve the time consuming and the expensive procedure 
caused by autologous cell transplantation116,117. 
 
For these apparent reasons, the present study thus chose to utilize a tissue based system, 
here a muscle tissue based model, to provide familiar internal milieu as that of an in 
vivo system together with a broader spectrum of tissue based response to the application 
of different morphogens and their combinations. Although it was difficult to observe 
tissue viability under a microscope, like in cell cultures, the IHC and qRT-PCR results 
confirmed that tissue can be made to survive in vitro and reflect accurately the process 
of morphogenesis as it might occur in vivo. The relative expressions of Col4α1, a 
biomarker for angiogenesis133,150-152, and the expression of VEGF-A, a marker for 
development and proliferation of endothelial cells153, were all up-regulated in all 
treatment groups throughout the 30 days in vitro culture period. Whilst the expressional 
level has to be carefully considered to in vivo based system, the fact that these two 
markers were increased confirmed that muscle tissue for use in assessing morphogen 
based related effects is an effective model that provides an accurate prediction of how 







4.2 Chondrogenesis: articular vs. non-articular 
The results of IHC and alcian blue staining showed that morphogenesis and specific 
ECM can be induced in a culture system by applying growth factors, on their own or in 
different combinations. ACAN, as in the IHC detection, is one of the abundant 
proteoglycans in the all types of cartilage as it is the fundamental for cartilage function 
and skeletal development154,155. Alcian blue first used by Steedman et al.156 as a 
selective dye for mucins in 1950 and then applied to stain acidic polysaccharides such 
as glycosaminoglycans in cartilages and other body structures157 was used in the study 
in conjunction with the IHC results to validate that chondrogenesis did indeed occur in 
vitro. In previous studies, Yoon and Lyons158 described that SOX9 was continuously 
expressed in chondrocytes up to the hypertrophic stage and was also involved in the 
BMPs induced chondrogenesis, which was consistent with our results of qRT-PCR. 
SOX9 served as the indicator for the initial activation of general chondrogenesis and 
regulated12,159,160 the transcriptional program by up-regulating Col2α1 and ACAN161-163. 
The significantly higher expression of ACAN and SOX9 genes in the experimental 
groups indicated the trend of chondrogenic morphogenesis. 
 
The polymeric extracellular framework is composed of collagen in almost all animal 
tissue164,165. The collagen type I, collagen type X and elastin are the unique components 
in fibrocartilage, hypertrophic cartilage and elastic cartilage, respectively, while the 
predominant compositions of hyaline cartilage are water (80%) and collagen type II 





assessed by qRT-PCR in this study. The absence of Col10α1 in nearly all experimental 
group under continuous stimulation suggested that the chosen three growth factors, 
BMP-2, OP-1 and TGF-β3, on their own or combinations could be inhibiting 
chondrocyte hypertrophy or endochondral ossification processes. Similarly, Gonzalez-
Fernandez et al.170 found that hypertrophy could be suppressed and more stable 
chondrogenesis be produced when TGF-β3 and BMP-2 were co-delivered with MSCs. 
Whilst, Cals et al. 171 did not find any significant TGF-β dependent differences along 
with the expression of Col10α1 other studies have also demonstrated that Col10α1 
expression increased during the chondrogenesis of MSCs without any BMPs172,173.  
 
Articular cartilage matrix is composed of 90-95% collagen type II and is the most 
sought after molecule during the tissue engineering of this matrix. Any other collagen 
or low levels of collagen type II content have been a thorn in the side of articular 
cartilage based therapies as most treatment revert to fibrocartilage or ossify 
completely174,175. The relative expression level of Col2α1 was significantly increased 
in all treatment groups in relation to controls when morphogens and their different 
combination were applied continuously for the 7 and 14 days in vitro culturing period, 
except the TGF-β3 group on day 7. This promising outcome would mean the muscle 
tissue was transforming itself towards a possible articular cartilage lineage, critical for 
tissue engineering prospect in healing arthritic defects. The negative CNRQ values of 
Col1α1 on day 7 and 14 irrespective of the type of morphogen used in the present study 





a fibrocartilage lineage. Hence, the results of the comparison between Col1α1 and 
Col2α1 on day 7 and 14 showed that continuous application of the chosen morphogens 
from the TGF-β supergene family of proteins had the capability of forming hyaline 
cartilage. While Wang et al.169 revealed that chondrocyte predominantly expressed 
collagen type I at the initial stage (1-3 days), even exceeding collagen type II, according 
to the time-dependent detections of cartilage-specific ECM protein in vitro, our study 
suggested otherwise perhaps as we used tissue and not cells and the lack of an early 
detection.  
 
However, whilst the initial findings at day 7 and 14 were indicative of a hyaline articular 
cartilage formation process, the observation in the recovery of Colα1 on day 30 in most 
experimental groups, suggested that fibrosis was in progress. One possible explanation 
was that the damaged cartilage was replaced by fibrocartilage consisting with a high 
amount of collagen type I176. Alternatively, other studies also showed that the 
ossification, which also relates to the expression of Colα1 may occur after 30 days, in 
vivo 133,177, strongly suggesting that 30 days as a terminal detection time point may be 
too early to make conclusions as there patterns of expression could deviate as culture 
time increases.. Long culture studies are necessary to eliminate this concern. Therefore, 
whether the relative expression of Col1α1 peaked before day 7, after day 30 or both, 
was unclear due to the limitation of detection time. Moreover, most of the experimental 
groups in which OP-1 was used maintained a significantly higher expression level of 





hyaline articular cartilage. However, the absence of the qRT-PCR results in some 
experimental group when amplifying Col2α1 made the analysis incomplete, which may 




4.3 The “withdrawal effect” 
The MOD values, reflecting the density of aggrecan, in most groups stimulated 
continuously for 14 and 30 days were significantly higher than that in the corresponding 
single 48h application groups, which may indicate that short-term stimulation does not 
invoke chondrogenic morphogenesis in muscle tissue. This was also reflected in the 
relative expression levels of ACAN, SOX9 and Col2α1. Jelicet al.181 demonstrated that 
prolonged application of OP-1 promoted better regeneration of articular cartilage in 
chondral defects compared to a single intra-articular injection. Therefore, the creation 
of a chondrogenic morphogenesis environment depends on the sustained role of growth 
factors. However, in vivo experiments performed by Neol et al.182 revealed that short-
term BMP-2 expression was sufficient to induce the osteochondral differentiation under 
a Tet-Off system. As such, there may be other factors that affect the stimulation of a 
single application to the muscle tissue and is worth considering. Ren et al.183, for 
instances, also used muscle tissue fragments and modified the cells of the tissue using 
adenoviral genetic technology, yet postulated that tissue wide change would only occur 





a possible flaw in the single 48h morphogen application administrations in which the 
release kinetics or possible signal transition did not effectively reach a functional 
concentration to cause a relevant stimulus. 
 
 
4.4 Chondrogenesis induction: synergistic morphogen combinations 
Toh et al.184 initially demonstrated that BMP subfamily could induce the formation of 
bone and cartilage in ectopic sites and act as autocrine and/or paracrine factor to 
regulate the development of bone and cartilage. They also described that BMP-2 
regulated the maturation of mesenchymal progenitors and promoted the synthesis of the 
chondrocyte matrix. By comparing the different effects of BMP-2, -4 and -6, Sekiya et 
al.185 suggested using BMP-2 to produce polysaccharide-rich cartilage quantities. 
Schmal et al.186 demonstrated the importance of BMP-2 in cartilage repair and 
maintenance through in vivo experiments. The present study results were in agreement 
with these published opinions in which it was speculated that BMP was the inducer of 
chondrogenic morphogenesis. On day 14, semi-quantitative histomorphometric 
analysis of IHC indicated that the group where BMP-2 was applied alone continuously 
had the highest MOD value, but then dropped sharply. The results of qRT-PCR showed 
the same pattern. The relative expressions of chondrogenic-related genes, such as 
ACAN, SOX9 and Col2α1 on day 7 in the group applied BMP-2 continuously were 
significantly higher than that in the other groups, but there was also a sharp decline in 





chondrocyte proteoglycans were synthesized earlier and stronger than TGF-β isoforms, 
but the duration was shorter. Additionally, several researchers have demonstrated that a 
short period of BMP‐2 expression or co-incubation time was necessary to induce bone 
regeneration or promote the osteogenic differentiation of MSCs in vitro188-191, which 
indicated that BMP-2 might not only serve as the inducer in the chondrogenesis, but 
also in osteogenesis192,193.  
 
Hellingman et al.194 demonstrated that phosphorylation of both SMAD 2/3 and SMAD 
1/5/8 was essential for initiating chondrogenic differentiation and these SMADs 
maintained their activity in differentiated MSCs, while only SMAD 2/3 was found in 
native articular cartilage. This evidence pointed out that induced articular 
chondrogenesis could only be maintained through the signaling involving SMAD 2/3 
regulated by TGF-β isoforms and may also explain the higher MOD in TGF-β3+ OP-1 
continuous stimulation group on day 30 and the stronger expression of ACAN and SOX9 
on day 14 and 30 in groups applied OP-1 + TGF-β3 and BMP-2 + OP-1 + TGF-β3 
continuously, respectively. While OP-1 up-regulated chondrocyte metabolism195-197, 
stimulated only cartilage-specific extracellular proteins198-200 and generated normal 
functional proteoglycans201, it explained why the expression of Col2α1 was stable in 
the experimental group containing OP-1. By analyzing the results of gene expressions 
over time in different experimental groups, the extreme decline from day 7 to 14 in the 
group using BMP-2 alone continuously over 30 days, was prevented by different 





sufficient to evoke chondrogenesis, but TGF-β3 and OP-1 are critical extra requirements 
for articular cartilage tissue engineering, especially in the middle and late stages of 
induction, as TGF-β3 and OP-1 help maintain the process. 
 
Interestingly, increased MOD and relative expression levels of chondrogenic-related 
genes induced by BMP-2 alone was inhibited by the addition of TGF-β3 or/and OP-1, 
showing an apparent antagonism effect. The possible explanation was that the TGF-β 
superfamily signal pathways can antagonize each other, although these mechanisms 
remain unclear202,203. First, it was hypothesized that BMP-2 was the most active growth 
factor during morphogenesis at the initial stage of addition until 7 days. Along this line 
of thought, it can be deduced that both SMAD 2/3 (regulated by TGF-βs) and SMAD 
1/5/8 (regulated by BMPs) need to interact with SMAD 4, which is a cofactor and 
prerequisite for the regulation of target genes transcription in which the competition led 
to antagonism between TGF-βs and BMPs119. The functions of TGF-βs in cartilage 
were reviewed by Wang et al.100, which indicated that TGF-βs could participate in both 
TGF-βs (SMAD 2/3) and BMPs (SMAD 1/5/8) signals. Kraan et al.92 elaborated a 
similar viewpoint that besides binding to ALK 5 via canonical pathway (SMAD 2/3), 
TGF-βs can also bind to ALK1 and ALK2 in some cell types to activate SMAD 1/5/8, 
thus activating the BMPs pathway. However, the extent to which TGF-βs utilized BMPs 
pathways in the present culture systems needs further evaluations. Moreover, Gronroos 
et al.204 described a relevant mechanism where TGF-βs inhibited BMP signaling by 





phosphorylation. Hence, TGF-βs and BMPs may serve sequentially in the regulation of 
cartilage differentiation205,206 and the antagonistic, as well as synergistic activities, 
which were dependent on the differentiation stage162,194,207. Because the current results 
have revealed the antagonism between the three growth factors in the early stages of 
tissue culture, in order to make up an optimal protocol, more details are needed and 
considered, such as erasing TGF-βs in the early stage and sequentially adding growth 
factors as culture time progress or removing them as required to generate a consistent 
articular cartilage formation response. 
 
 
4.5 The limitations 
In terms of limitations in the study, first, the detection mainly focused on and was 
limited to, chondrogenesis. However, the expressions of Col1α1, whose product also 
makes up more than 90% of bone matrix167, was recovering after day 7 in the present 
study. Although the evidence was insufficient, it was probable that not only did 
chondrogenesis occur, but also osteogenesis-related reactions were in progress in this 
culture system, which may attribute to the diverse response raised by various cell types 
in muscle tissue receiving the same stimulation. Many studies demonstrated that the 
response to the intervention of TGF-β superfamily proteins depended on the culture 
system or models used208-210. For these reasons, the spatial and temporal patterns of 







Second, although previous literature recommended certain growth factor 
concentrations, more experiments based on the gradient concentration are needed. 
Some investigators have shown that the biphasic effects of TGF-β superfamily can 
affect DNA synthesis208,209,211. Yang et al.212 also demonstrated that BMP-2 served as 
a double-edged sword in the osteogenic differentiation induction by TGF-β isoform 
activated kinase 1 in MSCs, which is regulated by different concentration of BMP-2. 
Additionally, the expressions of Col1α1 and Col10α1 were related to SMAD 7, which 
acted as an intracellular inhibitor of BMP and TGF-β isoform signaling and expression 
depends on the type of TGF-β signaling213-215. Therefore, it cannot be accurately 
concluded whether an inappropriate growth factor concentration caused the suppressed 
results of Col1α1, Col10α1 and even ALP. 
 
Compared with fresh tissue, the control group also showed up-regulation of genes, such 
as ACAN and SOX9, although significantly lower than the corresponding experimental 
groups stimulated continuously, indicating the chondrogenesis effect observed in the 
present study may not be wholly dependent on the application of growth factors. 
Fahlgren et al.216 demonstrated that the expression of BMP-7 in rabbit knee joint 
cartilage increased after a capsular incision. Several studies also showed that micro-
fractures in cartilage possess a chondroprotective effect and stimulate cartilage repair 
116,217,218. Therefore, it has to also be considered whether the damage caused by biopsy 





was a mechanical stimulus that brought about an increase in gene expression due to a 
local reaction. Future experiments will also thus need to assess the importance of 
mechanical219 in conjunction with the biological stimulation in muscle tissue based 
culture models seeking to generate articular cartilage. 
 
The fourth limitation of this study was that no corresponding antagonist, to BMPs or 
TGF-β3, was applied. The chondrogenesis observed was induced by the signals raised 
from multiple extracellular ligands simultaneously in vitro and via the different 
pathways, then integrating and interpreting them to respond appropriately204. However, 
the extent of specific signaling pathways functioning in the morphogenesis cannot be 
verified. Tsumaki et al.220 and Pathi et al.221 demonstrated the necessity of BMP 
signaling pathway by using Noggin to achieve specific blockade222,223. Moreover, many 
studies have shown that in addition to SMAD 2/3, TGF-βs can also phosphorylate 
SMAd1/5/8 which hitherto considered unique to BMPs, so the use of antagonists is 
required to prove whether TGF-βs had an impact through this pathway in our culture 
system in future studies. 
 
 
4.6 Future studies 
Given the limitations of the present study and the needs of the development of 
disciplines, numerous additional experiments have to be considered. First, more 





example, the Movat’s pentachrome stain, which assesses for collagen associated with 
chondrogenesis and osteogenesis, elastic fibers, muscle and other connective tissue224 
may address the temporal and spatial patterns of different morphogenesis. In addition, 
according to the recovery of Col1α1 at the final detection day 30, the time points should 
be increased and extended appropriately to generate more information about whether 
osteogenesis takes over after this time point or is a simple regulatory pattern that occurs 
once every few days. Additionally, five factors were previously proposed to elucidate 
bone and cartilage engineering development225: 1) cells directly involved in 
morphogenesis, 2) matrices produced by the cells, 3) body fluid, 4) regulators of 
cellular activities and morphogenesis progress and 5) biomechanical dynamics. Hence, 
the impacts of biomechanics on chondrogenic or osteogenic morphogenesis is another 
important aspect worth studying. To further analyze whether cells with various 
phenotypes respond differently to growth factors, alone or in combinations, it may also 
be necessary to consider a single cell type, such as muscle-derived stem cells, muscle 
fibroblasts or myoblasts. Finally, by increasing the application of antagonists, a more 
comprehensive understanding of growth factors can be achieved: whether there exists 
a specific pathway that is central in the articular chondrogenesis process and what is 
the exact functional time point at which different growth factors need to be added to 







Muscle tissue was shown to be a viable model in this chondrogenic induction study. 
The application of the member of TGF-β supergene family, alone or in combinations, 
can induce chondrogenesis in this tissue model, with the initial prospect being towards 
of hyaline cartilage composed primarily of Col2α1. Although the experiment attempted 
to achieve a more economic-efficiency induction scheme by 48h morphogen 
stimulation withdrawal study, it has shown that single stimulation of growth factor was 
insufficient to evoke the relevant response, in which only continuous morphogen 
application could generate the desired response in which it was critical the type of 
morphogens was used and when they were used. In terms of different effects caused by 
growth factors, alone or combinations, BMP-2 alone was sufficient to initiate 
chondrogenesis, which could be inhibited by the addition of TGF-β3 or/and OP-1. 
However, the TGF-β3 and OP-1 were necessary for cartilage tissue engineering, 
especially in the middle and late stages of chondrogenic induction. Although limitations 
still exist, the present study shows the importance of TGF-β supergene family proteins 
in tissue engineering, providing a novel approach and strategy for the production of 








ACTB   Actin beta  
ACAN   Aggrecan  
ALK   Activin receptor-like kinases  
ALP   Alkaline phosphatase  
BMP   Bone morphogenetic protein  
CDS   Coding sequences  
CNRQ   Calibrated normalized relative quantities  
Col10α1  Collagen type X alpha 1  
Col1α1   Collagen type I alpha 1  
Col2α1   Collagen type II alpha 1  
Col4α1   Collagen type IV alpha 1  
Cq    Cycle quantification 
Ct    Cycle threshold Value  
DI water  Deionized water  
ECM   Extracellular matrix  
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase  
GDFs   Growth and differentiation factors  
IHC   Immunohistochemistry  
IOD   Integrated optical density value  





MIQE Minimum Information for Publication of Quantitative Real-Time 
PCR Experiments  
mL    Milliliter 
mM   Millilimole 
mm    Millimeter 
MOD   Mean optical density value  
MSCs   Mesenchymal stem cells  
mTOR    Mammalian target of rapamycin 
ng    Nanogram 
OP-1   Osteogenic protein 1  
POLR2e  RNA polymerase II subunit e  
qRT-PCR  Quantitative reverse-transcriptase polymerase chain reaction  
RNA28S4  RNA-28S ribosomal 4  
RPL13α   Ribosomal protein L13α  
RPLP0   Ribosomal protein lateral stalk subunit P0  
R‐SMADs  Receptor-regulated SMAD proteins  
SDHA   Succinate dehydrogenase complex flavoprotein sub-unit A  
SOX 9   Sex-determining region Y (SRY)-box 9 
TBP   TATA-binding protein  
TGF-β   Transforming growth factor beta  
VEGF-A  Vascular endothelial growth factor A  





ΔG    Gibbs standard free-energy change  
μL    Microliter 
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Appendix 1. Statistical comparison of CNRQs of different genes at adjacent time points in experimental groups stimulated for 48h 
Group Time (day) Genes   
Col1α1 Col2α1 Col4α1 Col10α1 ACAN ALP SOX9 VEGF-A 
Control 7 0.17±0.21 0.22±0.10 0.49±0.12 -0.66±0.12 0.88±0.10 -0.79±0.0 0.13±0.07 0.12±0.1 
14 0.17±0.19 -0.21±0.1 0.27±0.06 -0.21±0.28 0.98±0.12 -1.06±0.0 0.23±0.01 0.88±0.1 
30 0.58±0.17 -0.16±0.0 -0.11±0.0 -0.46±0.28 1.31±0.47 -1.30±0.1 0.70±0.09 1.26±0.1 
7 vs. 14 P-value 0.9987 0.0001 0.0022 0.0296 0.8527 0.0145 0.0513 <0.0001 
14 vs. 30 P-valu 0.014 0.7822 <0.0001 0.2635 0.2044 0.0331 <0.0001 0.0004           
BMP-2 7 -0.26±0.12 0.55±0.17 -0.26±0.12 -0.36±0.94 0.76±0.16 -0.85±0.12 0.10±0.10 0.11±0.12 
14 0.35±0.11 -0.21±0.19 0.35±0.11 -0.44±0.10 1.08±0.61 -0.96±0.10 0.29±0.12 -0.20±0.1 
30 0.67±0.15 -0.27±0.14 0.67±0.15 -0.64±0.00 1.46±0.49 -1.04±0.36 -0.46±0.28 0.61±0.18 
7 vs. 14 P-value <0.0001 <0.0001 0.0023 0.9753 0.3628 0.6808 0.0881 0.0002 
14 vs. 30 P-valu 0.0021 0.9829 <0.0001 0.8971 0.2344 0.8876 <0.0001 <0.0001           
TGF-β3 7 0.20±0.15 0.58±0.26 0.20±0.15 -0.63±0.27 0.43±0.10 -1.09±0.05 -0.02±0.16 0.18±0.06 
14 0.29±0.13 -0.50±0.20 0.29±0.13 -0.34±0.04 0.44±0.23 -1.17±0.14 0.14±0.09 -0.13±0.0 
30 0.72±0.10 -0.21±0.12 0.72±0.10 -0.76±0.09 1.22±0.42 -1.33±0.07 -0.16±0.08 0.65±0.12 
7 vs. 14 P-value 0.6166 <0.0001 0.6166 0.0686 0.9994 0.6855 0.0395 <0.0001 
14 vs. 30 P-valu <0.0001 0.0973 <0.0001 0.0231 <0.0001 0.1673 <0.0001 <0.0001           





14 0.31±0.09 -0.35±0.16 0.31±0.09 -0.05±0.07 0.59±0.29 -0.98±0.21 0.09±0.03 0.21±0.09 
30 0.64±0.26 -0.22±0.15 0.64±0.26 -0.65±0.12 1.61±0.28 -1.13±0.20 -0.41±0.13 0.74±0.09 
7 vs. 14 P-value 0.0009 <0.0001 0.0009 <0.0001 0.0044 0.945 0.8438 0.7278 




7 -0.11±0.18 -0.22±0.22 -0.11±0.18 -0.81±0.43 1.23±0.40 -1.11±0.23 0.01±0.04 0.12±0.05 
14 0.24±0.12 -0.42±0.01 0.24±0.12 -0.36±0.34 0.03±0.10 -1.32±0.02 -0.04±0.08 -0.03±0.1 
30 0.60±0.18 -0.20±0.16 0.60±0.18 -0.49±0.01 1.23±0.19 -1.15±0.10 -0.48±0.23 0.61±0.08 
7 vs. 14 P-value 0.0001 0.3083 0.0001 0.1244 <0.0001 0.0378 0.8091 0.0013 




7 -0.54±0.28 0.58±0.19 -0.54±0.28 -0.63±0.20 1.34±0.39 -1.23±0.11 -0.03±0.16 0.13±0.21 
14 0.24±0.09 -0.36±0.34 0.24±0.09 -0.17±0.35 0.45±0.40 -1.22±0.09 0.13±0.10 -0.01±0.0 
30 0.73±0.17 0.25±0.08 0.73±0.17 -0.01±0.26 1.17±0.19 -0.73±0.20 -0.34±0.08 0.62±0.10 
7 vs. 14 P-value <0.0001 <0.0001 <0.0001 0.0529 <0.0001 0.9986 0.0247 0.1389 





7 -0.15±0.09 0.33±0.27 -0.15±0.09 NA 0.71±0.52 -1.51±0.15 -0.33±0.06 0.04±0.13 
14 0.33±0.31 -0.55±0.14 0.33±0.31 -0.49±0.21 0.57±0.46 -1.26±0.12 0.28±0.31 0.06±0.10 
30 0.83±0.13 0.11±0.28 0.83±0.13 -0.79±0.04 1.09±0.55 -0.80±0.15 -0.26±0.04 0.60±0.11 
7 vs. 14 P-value <0.0001 <0.0001 <0.0001 NA 0.9055 0.0091 <0.0001 0.979 
14 vs. 30 P-valu <0.0001 <0.0001 <0.0001 0.0526 0.0914 <0.0001 <0.0001 <0.0001           
BMP-2 
+ 
7 -1.14±0.54 0.14±0.24 -1.14±0.54 NA 0.82±0.60 -1.09±0.11 0.17±0.14 0.21±0.07 










30 0.54±0.38 0.41±0.12 0.54±0.38 0.05±0.50 0.77±0.15 -0.52±0.15 -0.34±0.11 0.26±0.04 
7 vs. 14 P-value <0.0001 0.0634 <0.0001 NA 0.9653 0.0115 0.0598 <0.0001 
14 vs. 30 P-valu 0.5243 0.0007 0.5243 0.2226 0.8932 0.2308 <0.0001 <0.0001 
All data are presented as mean ± standard deviation. The comparation was performed using ANOVA. We define p<0.05 as a statistically significant difference (in bold). 
CNRQ: Calibrated normalized relative quantity, Col1α1: Collagen Type I Alpha 1, Col2α1: Collagen Type II Alpha 1, Col4α1: Collagen Type IV Alpha 1, Col10α1: 
Collagen Type X Alpha 1, ACAN: Aggrecan, ALP: Alkaline phosphates, SOX9: SRY (Sex Determining Region Y)-Box 9, VEGF-A: Vascular endothelial growth factor 





Appendix 2. Statistical comparison of CNRQs of different genes at adjacent time points in experimental groups stimulated continuously 
Group Time (day) Genes   
Col1α1 Col2α1 Col4α1 ACAN ALP SOX9 VEGF-A 
Control 7 0.17±0.21 0.22±0.10 0.49±0.12 0.88±0.10 -0.79±0.0 0.13±0.07 0.12±0.10 
14 0.17±0.19 -0.21±0.1 0.27±0.06 0.98±0.12 -1.06±0.0 0.23±0.01 0.88±0.12 
30 0.58±0.17 -0.16±0.0 -0.11±0.0 1.31±0.47 -1.30±0.1 0.70±0.09 1.26±0.11 
7 vs. 14 P-value 0.9987 0.0001 0.0022 0.8527 0.0145 0.0513 <0.0001 
14 vs. 30 P-valu 0.014 0.7822 <0.0001 0.2044 0.0331 <0.0001 0.0004          
BMP-2 7 -0.66±0.1 4.71±0.12 0.58±0.10 3.91±0.13 1.83±0.06 0.72±0.13 0.08±0.08 
14 -0.34±0.1 0.67±0.08 0.43±0.05 2.15±0.18 -0.86±0.1 0.40±0.07 0.82±0.13 
30 0.23±0.14 0.04±0.75 0.20±0.09 2.04±0.26 -1.12±0.1 0.26±0.05 1.09±0.07 
7 vs. 14 P-value 0.025 <0.0001 0.0341 <0.0001 <0.0001 0.0004 <0.0001 
14 vs. 30 P-valu 0.0004 0.1382 0.002 0.6802 0.0194 0.0725 0.0024          
TGF-β3 7 -0.37±0.2 0.53±0.47 0.41±0.15 1.98±0.18 -0.84±0.1 0.34±0.15 1.01±0.15 
14 -0.38±0.1 0.87±0.06 0.19±0.06 2.50±0.15 -0.92±0.1 0.39±0.06 1.03±0.08 
30 0.86±0.07 NA 0.11±0.03 2.66±0.20 -1.29±0.1 0.36±0.05 0.92±0.11 
7 vs. 14 P-value 0.9821 0.3104 0.0104 0.0016 0.7578 0.6964 0.9504 
14 vs. 30 P-valu <0.0001 NA 0.3744 0.3406 0.0085 0.8434 0.3559          
OP-1 7 -0.62±0.2 0.57±0.09 0.30±0.10 1.57±0.33 -0.78±0.1 0.43±0.04 1.10±0.02 
14 -0.01±0.0 0.73±0.16 0.50±0.06 2.78±0.11 -0.92±0.2 0.36±0.05 0.96±0.20 
30 0.14±0.11 0.95±0.13 0.43±0.09 2.39±0.11 -1.07±0.1 0.32±0.07 1.03±0.09 









7 -0.60±0.0 0.68±0.03 0.58±0.05 2.49±0.08 -0.77±0.1 0.52±0.07 0.98±0.02 
14 -0.43±0.0 1.12±0.18 0.12±0.13 2.17±0.06 -1.04±0.1 0.48±0.05 1.09±0.06 
30 0.05±0.10 0.09±0.48 0.43±0.15 2.23±0.10 -1.34±0.0 0.31±0.03 1.34±0.02 
7 vs. 14 P-value 0.0219 0.1023 0.0001 0.0001 0.0126 0.4726 0.0009 




7 -0.75±0.0 0.67±0.14 0.61±0.07 1.75±0.23 -1.05±0.2 0.40±0.01 1.09±0.06 
14 -0.62±0.2 0.82±0.16 0.25±0.22 2.29±0.17 -0.85±0.1 0.36±0.04 0.90±0.15 
30 -0.10±0.0 NA 0.02±0.01 1.99±0.17 -1.38±0.0 0.28±0.10 1.09±0.01 
7 vs. 14 P-value 0.2641 0.3566 0.0027 0.0018 0.1791 0.5903 0.0171 





7 -0.67±0.1 0.73±0.09 0.43±0.10 1.53±0.21 -0.77±0.1 0.37±0.09 1.04±0.09 
14 -0.21±0.1 0.69±0.17 0.43±0.13 2.84±0.24 -0.88±0.0 0.51±0.04 0.93±0.03 
30 0.47±0.07 0.93±0.20 0.41±0.11 2.37±0.18 -0.81±0.1 0.40±0.03 1.24±0.04 
7 vs. 14 P-value 0.0002 0.931 0.9988 <0.0001 0.3732 0.01 0.0238 






7 -0.80±0.1 0.75±0.12 0.72±0.11 2.49±0.18 -0.49±0.2 0.63±0.17 1.16±0.02 
14 -0.25±0.0 0.79±0.49 0.69±0.05 2.25±0.07 -0.64±0.3 0.46±0.13 1.12±0.06 
30 0.58±0.10 0.84±0.09 0.32±0.05 3.27±0.13 -1.26±0.1 0.49±0.05 1.33±0.01 
7 vs. 14 P-value <0.0001 0.9814 0.8555 0.0423 0.6518 0.1334 0.1281 





 All data are presented as mean ± standard deviation. The comparation was performed using ANOVA. We define p<0.05 as a statistically significant 
difference (in bold). CNRQ: Calibrated normalized relative quantity, Col1α1: Collagen Type I Alpha 1, Col2α1: Collagen Type II Alpha 1, Col4α1: 
Collagen Type IV Alpha 1, ACAN: Aggrecan, ALP: Alkaline phosphates, SOX9: SRY (Sex Determining Region Y)-Box 9, VEGF-A: Vascular endothelial 
growth factor A. NA: Not available. 
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